No clinical trials have been attempted with PPAR-α agonists in sepsis, which may be due to the cardiac, skeletal muscle, renal, and bone marrow toxicities caused by PPAR-α agonist in clinical trials for patients with atherogenic hypercholesterolemia or dyslipidemia (228). This evidence concerns the gene PPARA and metabolic syndrome.